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Abstract
Background: Liver inflammation due to HCV infection leads to fibrosis, which is an independent predictor of
treatment response to interferon therapy in Chronic Hepatitis C (CHC) patients. This relationship has not been
studied for liver inflammation on pretreatment liver biopsy and End of Treatment Response (ETR). ALT is a less
invasive test than liver biopsy for measuring liver inflammation. Aim of this study was to compare ETR to Interferon
α (recombinant Interferon) & Ribavirin in CHC patients having higher and lower grades of liver inflammation and to
determine the diagnostic accuracy of pretreatment ALT for grades of liver inflammation.
Methods: A retrospective cohort of 876 naïve CHC patients, who completed Interferon α & Ribavirin for 24 weeks,
was studied for ETR. Pretreatment grade of inflammation on liver biopsy was taken as the exposure variable. It was
classified as high if there was moderate or severe and low if there was minimal or mild. Multivariable logistic
regression modeling was performed. Diagnostic accuracy of pretreatment ALT for liver inflammation grades was
determined by computing Area Under the Receiver Operator Curve (AUROC).
Results: Of all patients, 672 having diagnostic liver biopsy and ETR available were analyzed. Among them, 103 had
high and 569 had low grades of liver inflammation. Mean age was 36.9 (SD 9.1) years, with patients with high
grades being older than those with low grades inflammation (p = 0.03). High grades of liver inflammation was
associated with ETR (RR 1.17, 95% CI 1.12–1.18) adjusting for age, Total Leukocyte count (TLC) and pretreatment
levels of ALT, irrespective of liver fibrosis. This relation remained significant for ‘bridging fibrosis and cirrhosis’ and
not for ‘no’ or ‘portal fibrosis’. AUROC of pretreatment ALT for males and females was moderately accurate for
severe inflammation compared to minimal inflammation and less accurate for high grades compared to low
grades.
Conclusions: ETR in patients with higher grades of liver inflammation was 17% higher than those with lower
grades irrespective of fibrosis and 9% higher for bridging fibrosis and cirrhosis. Pretreatment ALT was moderately
accurate for severe inflammation only on liver biopsy in both males and females.
Background
Hepatitis C virus (HCV) is affecting 170 million people
worldwide [1], 8 million in Pakistan alone [2]. The viral
entry into the host activates T-helper cells as well as the
cytotoxic T-cells for elaborating inflammatory cytokines in
liver [3]. If the cellular immune response remains ineffect-
ive in clearance of the virus, it leads to hepatocellular
injury depicted by chronic inflammation, and ultimately to
liver fibrosis and cirrhosis [3]. Various quantitative grading
systems are used to measure liver cells insult on biopsy; of
these, modified Histological Index (HAI) [4] is commonly
used in Pakistan. Serum Alanine aminotransferase (ALT)
is a less invasive biochemical marker for indicating liver
cell injury than liver biopsy.
In Pakistan, HCV genotype 3 is predominant with
prevalence of 75–90%, from the six known HCV geno-
types [5]. Standard therapy for naïve Chronis Hepatitis
C (CHC) patients in this country is by Interferon α
(recombinant/conventional Interferon) 3 million units
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subcutaneously thrice weekly and Ribavirin 800 mg/day
for 24 weeks [6]. End of Treatment Response (ETR) to
this therapy is 71–86.5% while Sustained Viral Response
(SVR) is 52.3–86.3% [6].
This treatment costs about $ 800–1,000 per patient
per month [6]. Given that health care is paid by individ-
ual patients, many CHC patients rely on government
based subsidized treatment supposedly available in pub-
lic hospitals; nevertheless majority have to pay by pocket
for one or the other reason at many public and all of the
private hospitals [6]. Pegylated Interferon is not adminis-
tered to naïve CHC patients in Pakistan due to its high
cost. Only the patients who do not respond (ETR nega-
tive: PCR for HCV RNA positive at end of 24 weeks of
completion of treatment) to Interferon α (recombinant)
and Ribavirin therapy are considered for Pegylated Inter-
feron α & Ribavirin based on favorable predictors [6].
HCV genotypes 2 and 3, low viral load (< 2 million
IU/ml), absence of cirrhosis, mild or absent portal fibro-
sis on pretreatment liver biopsy are favorable predictors
for response to standard Interferon α and Ribavirin ther-
apy [7-9]. American Association for the Study of Liver
Disease (AASLD) practice guidelines recommend quan-
titative PCR for HCV RNA for quantification of viral
load and HCV genotyping prior to antiviral therapy in
CHC patients [10]; same has been proposed by the
European Association for the Study of the Liver (EASL)
[11]. These tests are not routinely done in Pakistan due
to its high costs and lack of standardized procedures [6].
However, liver biopsy is performed to a larger extent at
the HCV treatment clinics. According to the EASL
guidelines published in 2011, liver biopsy is still the
reference method for measuring liver inflammation and
fibrosis, which tells about the liver disease severity prior
to the therapy [11].
Few studies report whether histological variables other
than fibrosis on liver biopsy, like grade of inflammation,
can predict the response to antiviral therapy in CHC
patients, showing conflicting results. Study by Daboul I
et al. in Ohio, USA showed that response at 12 weeks
(EVR positive) in CHC patients with high grades of liver
inflammation was 60% compared to 68% in those with
low grades when treated with Pegylated Interferon and
Ribavirin [12]. Another study in the Middle East
reported positive correlation between response rate after
24 weeks of stopping the therapy (SVR positive) and
liver inflammation [13]. The former was conducted in
HCV genotype 1 [12] and the latter in HCV genotype 4
patients [13]. Moreover, both studies have small sample
size affecting the internal validity. Therefore relationship
of ETR to Interferon α (recombinant/conventional Inter-
feron) and Ribavirin therapy for 24 weeks with high and
low grades of liver inflammation in CHC patients
remains unknown for HCV genotype 3 patients.
Upper limit of normal (ULN) ALT levels for patients
with liver inflammation was 40 U/L in males and
30 U/L in females [14]. The new upper limit of nor-
mal of ALT for identification of patients with minimal
to mild liver inflammation are defined as 30 U/L in
males and 19 U/L in females [14]. These results are
based on investigations in Western population; and
sensitivity and specificity at these new levels for min-
imal to mild liver inflammation are 76% and 97% re-
spectively [14].
The primary objective of this study was to compare
ETR in CHC patients with higher grades to those with
lower grades of pretreatment liver inflammation. Our
secondary objective was to determine diagnostic accur-
acy of ALT for pretreatment grades of inflammation
ascertained by modified HAI for grading liver inflamma-
tion on liver biopsy in CHC patients.
Methods
Study design & setting
A retrospective cohort of 876 naïve CHC patients, who
received Interferon α & Ribavirin for 24 weeks between
March 1998 and June 2009 was assembled. Pre-
treatment grade of liver inflammation was the exposure
variable and ETR ascertained by qualitative PCR for
HCV RNA at completion of 24 weeks of Interferon α
(recombinant/conventional Interferon) 3 million units
subcutaneously thrice weekly and Ribavirin 800 mg/day
therapy was taken as the outcome variable. Data were
collected from medical records of the CHC patients
treated at Holy Family hospital (HFH) in Rawalpindi
and Aga Khan University hospital (AKUH) in Karachi,
using a pretested structured Questionnaire. HFH is a
government tertiary care hospital affiliated to Rawalpindi
Medical College, Rawalpindi, which besides catering
patients from Rawalpindi and Islamabad, also provides
care to patients coming from surrounding parts of
major provinces of Pakistan namely Punjab, Khyber
Pakhtunkhwa and Northern areas of Pakistan. Prime Minis-
ter’s programme for control of hepatitis B and C was
initiated in this hospital in the second half of 2006, after
which the patients of CHC started getting regular treat-
ment free of cost (cost for 24 weeks Interferon α and Riba-
virin therapy is paid by the government) as per guidelines
of Pakistan society of gastroenterology at this liver clinic.
AKUH is one of the advanced private tertiary care hospital
in Karachi, which caters patients from the largest city of
Pakistan, Karachi and the other two provinces namely
Sind and Balochistan. CHC patients treated at AKUH
have to pay for their 24 weeks Interferon α and Ribavirin
therapy themselves (out of pocket), though some are
sponsored by private, semi private and government
employees for their treatment.
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Study population
Naïve CHC patients attending the above mentioned out
patient department of medicine at the two hospitals, re-
ceiving Interferon α (recombinant/conventional Inter-
feron) 3 million units subcutaneously thrice weekly and
Ribavirin 800 mg/day therapy for 24 weeks after having
pretreatment liver biopsy were included. Those with de-
compensated liver disease, liver failure, other liver path-
ologies (like hepatitis B, haemochromatosis, liver cancer
etc.) and renal insufficiency were excluded.
Study variables and data management procedures
Data were collected for demographic (age, gender), and
biological characteristics; baseline hematological investiga-
tions like hemoglobin (Hb), total leukocyte count (TLC)
and biochemical investigations (serum ALT, AST, biliru-
bin, alkaline phosphatase), HCV genotype, HCV viral load
by quantitative HCV for RNA at the start of the therapy,
liver inflammation and fibrosis at liver biopsy by modified
HAI or Batts BLS, Early Viral Response (EVR) measured
by qualitative PCR for HCV RNA at 12 weeks of therapy
and ETR by a trained data collector on the Performa. Pre-
treatment grade of liver inflammation was graded on liver
biopsy by using modified HAI [4]. Liver inflammation was
defined as high grades if the patient had moderate (inflam-
mation score 9–12) or severe inflammation (inflammation
score 13–18). It was defined as low grades if the patient
had minimal (inflammation score 1–4) or mild inflamma-
tion (inflammation score 5–8). ETR was measured by
qualitative PCR for HCV RNA at 24 weeks of completion
of Interferon α & Ribavirin therapy [6]. It was termed as
‘positive’ if qualitative PCR for HCV RNA was negative
and ‘negative’ if qualitative PCR for HCV RNA was posi-
tive [6].
Manual of operation and key document were made for
the training of the data collector. Rechecking of other data
sources like pathology lab reports were done in case of
missing data on the medical record file. Completeness and
correct data entry was verified and logical consistency of
the recorded data was checked by the Principal Investigator
(PI) daily for all the forms. Data entry programme was
developed in ‘Epi Info’ version 6.04 (CDC, USA) [15]. Two
independent data entry operators entered the data. Errors
in the two entries were checked by generating an ‘error list’
which showed an error of 0.26%. PI validated the values on
‘error list’ against those in the questionnaire. These correc-
tions were then made in the entered data by the data entry
operators. Further, the entire corrected database was vali-
dated by the PI against the questionnaires.
Ethical considerations
Confidentiality of all the participants was maintained by
assigning code to each of them. Identification information
was accessible to the PI only. Study was conducted after
ethical approval by Ethical Review Committee of the
AKUH after receiving letter of collaboration from HFH
(June 22, 2009 under ERC number 1260-CHS/ERC-09).
Statistical methods
Sample size was calculated using the software ‘Sample
size determination in health studies-A practical manual’
version 2.0 (WHO) [16]. Taking proportion of disease
(non responders, Qualitative PCR for HCH RNA posi-
tive) in exposed (high grades of inflammation) at the end
of therapy as 40% [12], anticipated Relative Risk (RR) as
1.5, level of significance as 5% and power as 80%, at least
196 patients were required in each inflammation group.
Taking the ratio of High to Low grades of liver inflam-
mation as 1:4 [13], and anticipated missing data as 10%,
at least 137 patients were required with high grades and
545 required with low grades of liver inflammation.
Statistical analysis was done using SPSS version 14
[17]. Mean and Standard Deviation (SD) are reported for
continuous variables having normal distribution; median
and Inter Quartile Range (IQR) for continuous variables
having skewed distribution. Proportions are reported for
categorical variables. Student’s t-test (or Mann Whitney
U test in case of skewed distribution) were used as tests
of significance for comparing continuous variables be-
tween the patients having high grades of liver inflamma-
tion to those having low grades. Chi-square test (or
Fisher exact test in case of cell count less than 5) was
conducted to compare the difference of categorical vari-
ables between the two groups of liver inflammation.
Patients who were eligible for the study but did not
complete the Interferon α & Ribavirin therapy for 24 weeks
were compared to those who completed it to account for
differences by baseline characteristics to address selection
bias. P-value of< 0.05 was considered significant. Univari-
able logistic regression model was built and variables with
p-value on likelihood ratio test less than 0.25 or biologic-
ally significant, were considered for the multivariable ana-
lysis. As liver inflammation is one of the factors for liver
fibrosis [3] and it is known that high fibrosis is a poor pre-
dictor of response to Interferon therapy [7-9], liver fibrosis
may have had a confounding effect and therefore analysis
was also performed stratified on liver fibrosis (no fibrosis,
portal fibrosis, bridging fibrosis and cirrhosis). For discrete
variable (liver fibrosis in this case), stratified analysis is
equivalent to adjustment of covariate using regression
analysis [18]. As the sample size was large in this study
and sparse data problem was not encountered, thus strati-
fied analysis was attempted. EVR was found to be signifi-
cant but having unavailable information for more than
15% of patients, was not included in modeling further.
Multivariable analysis was based on patients having infor-
mation on all the study variables required for model build-
ing (significant on univariable analysis or having biological
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significance). Imputation for missing values was not
attempted as it was computationally difficult. Moreover
imputing the missing values of continuous variables like
ALT, AST and TLC with averages preserves the sample
mean but the co-variance structure is distorted to the ex-
tent that estimates are biased towards zero. If regression is
used for imputation, observed correlations are inflated
and biased away from zero [19]. Unadjusted and adjusted
Relative Risk (RR) and their 95% Confidence Interval (CI)
were calculated. Interactions were explored between vari-
ables and confounding effects were checked, Hosmer and
Lemeshow goodness of fit statistic was applied after
checking for the co-variate pattern. P-value of >0.05 indi-
cates that the model fits adequately.
Mean (SD) of pretreatment ALT (normally distributed)
was computed for minimal, mild, moderate and severe
liver inflammation group separately for males and
females. Sensitivity and specificity of pretreatment ALT
for mild, moderate and severe inflammation were calcu-
lated compared to minimal inflammation at deciles of
ALT. Receiver operating characteristic (ROC) curves
were plotted and Area Under the Receiver Operator
Curve (AUROC) computed. ROC curves were also plot-
ted for high grades of liver inflammation taking low
grades liver inflammation as the reference category sep-
arately for males and females. Based on AUROC, accur-
acy of pretreatment ALT for the grade of inflammation
was defined as non-informative (AUC= 0.5), less accur-
ate (0.5<AUC ≤ 0.7), moderately accurate (0.7<AUC ≤
0.9), highly accurate (0.9<AUC< 1) and perfect
(AUC=1) [20]. Cut off values of pretreatment ALT for
mild, moderate and severe inflammation compared to
minimal inflammation, and high grades liver inflamma-
tion compared to low grades was decided based on opti-
mal level of sensitivity and specificity i.e. the upper left
most part of the ROC curve [20].
Results
A total of 1,045 records were screened, of which 672
patients completed the 24 week Interferon α and
Ribavirin therapy and had diagnostic liver biopsy
(Figure 1). One hundred and twenty patients did not
complete the 24 week Interferon α & Ribavirin therapy.
These patients had significantly higher Hb, TLC and bili-
rubin compared to those who completed the therapy
(Table 1). There was no difference in grades of liver in-
flammation (p = 0.26) nor liver fibrosis (p = 0.57) between
the patients who did not complete the therapy and those
who completed it. Genotype data for HCV was available
in 101 patients; 94% of them had genotype 3. Distribu-
tion of HCV genotypes did not vary between the patients
who did not complete the therapy and those who com-
pleted it (p = 0.85). Quantitative PCR for HCV RNA
prior to therapy was available in 141 patients, median
513,866 IU/mL (IQR 493–79,121,294 IU/mL). The
patients who completed the 24 week Interferon α &
Ribavirin therapy did not differ significantly from those
who did not complete it with regards to the viral load
(median 508,551 IU/mL vs. 594,217 IU/mL, p = 0.30)
(Table 1).
Patients with high grades of liver inflammation were
older than those with low grade (Table 2). The two
groups did not differ with regards to gender distribution
(Table 2). Mean Hb and mean pretreatment ALT were
significantly higher while mean albumin was significantly
lower in those with high grade liver inflammation com-
pared to low grade (Tables 2 and 3). High grade inflam-
mation group significantly differed from those with low
grade with respect to liver fibrosis: no fibrosis (18.4% vs.
58.2%), portal fibrosis (35.9% vs. 33%), bridging fibrosis
(20.4% vs. 7.6%) and cirrhosis (25.2% vs. 1.2%) respect-
ively, depicting a p-value of <0.01.
Univariable logistic regression showed that, age< 40
years, male gender and EVR positive was positively asso-
ciated with ETR, while increase in TLC was negatively
associated with ETR positive (Table 4). Multivariable ana-
lysis depicted that ETR positive was 1.17 times (95% CI
1.12–1.18) higher in high grades group compared to those
with low grades of liver inflammation; adjusting for age,
pretreatment TLC and pretreatment ALT (Table 5).
Hosmer and Lemeshow test for goodness of fit showed chi
– square statistics as 6.23 (p-value 0.621) implying that the
model fits well. Stratified analysis showed that ETR positive
was 1.09 times (95% CI 1.02–1.19) higher in high grades
group compared to those with low grades for patients hav-
ing bridging fibrosis and cirrhosis. The association of ETR
with grade of liver inflammation was neither significant in
those having no fibrosis (RR 0.97, 95% CI 0.68–1.07) nor in
those having portal fibrosis (RR 1.02, 95% CI 0.95–1.03).
These latter three models were adjusted for age, pretreat-
ment TLC and pretreatment ALT.
Mean levels of pretreatment ALT increased as the liver
inflammation increased and was less in females as com-
pared to males for all inflammation groups (Figure 2).
AUROC showed that pretreatment ALT was moderately
accurate for severe inflammation in both males and
females (Figure 3). It did not correlate well with mild
and moderate liver inflammation (Figures 4 and 5). Tak-
ing low grades of liver inflammation as the reference cat-
egory, pretreatment ALT was less accurate (AUROC=0.67)
in males as well as in females (AUROC=0.64) for high
grades of liver inflammation.
According to the optimization of sensitivity and speci-
ficity, cut-off levels of 53 U/L, 65 U/L and 75 U/L indi-
cated mild, moderate and severe liver inflammation
respectively in females. While cut-off levels of 68.4 U/L,
85 U/L and 118 U/L can be used to indicate mild, mod-
erate and severe liver inflammation in males respectively.
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In females pretreatment ALT level of 71 U/L indicates
high grades liver inflammation while a value of 86.5 U/L
indicates high grades of liver inflammation in males.
Discussion
Higher grades of inflammation (moderate or severe) on
pretreatment liver biopsy, younger age (<40 years) and
TLC count of less than 7.2 cells × 109/L before initiation
of therapy were independent predictors of positive ETR
in naïve CHC patients. Pretreatment ALT is a moder-
ately accurate test for indicating severe inflammation on
pretreatment liver biopsy in both male and female CHC
patients; who have not been previously treated for
chronic HCV infection.
The relationship between higher grades of inflammation
and positive ETR is consistent with the finding of Derbala
MF et al. who reported positive correlation (p-value
< 0.05) between higher grades of inflammation and re-
sponse rate (SVR positive) in HCV genotype 4 patients
treated with Pegylated Interferon and Ribavirin for one
year [13]. These finding are also biologically plausible.
HCV activates the cytotoxic T-lymphocytes which releases
inflammatory cytokines that causes liver inflammation in
CHC patients [21]. Grade of liver inflammation correlates
with the underlying immune response of the host i.e.
higher the immune response to HCV infection, higher is
the liver inflammation [22]. Interferon α is a cytokine that
has two modes of action: direct antiviral affect as well as it
acts as an immunomodulator to clear HCV infection [23].
Therefore high grades of liver inflammation depicts higher
immune response to HCV which responds more to im-
mune modulation effect of Interferon α compared to low
grades of inflammation. But this finding remains true for
patient with bridging fibrosis and cirrhosis only as found
in our study.
The two inflammation groups varied significantly with
regards to age; and this finding is also similar to a study
conducted in China which showed that increasing age cor-
related with the inflammatory activity (p-value< 0.05)
[24]. Literature supports the positive relationship of
younger age (< 40 years) and positive ETR. Poynard T
et al. in their study showed that SVR positive to Interferon
α-2b and Ribavirin for duration of 48 weeks in
patients≤ 40 years was 48% compared to 34% in those
more than 40 years of age [25]. Young age at the start of
treatment was significantly positively associated with re-
sponse to combination therapy of Interferon α and
Ribavirin in other studies as well [23]. We also noted that
baseline characteristics of the CHC patients who completed
Interferon α and Ribavirin therapy for 24 weeks in this
study are comparable to the CHC patients in Pakistan.
Mean age of patients was 36.8 (SD 9.1) years which is
Medical records 
reviewed (1045) Excluded 
Liver biopsy missing (26) 
HBV + HCV (19) 
Renal insufficiency (4) 
Incomplete therapy 
(120) 
Liver biopsy not 
diagnostic (125) 
ETR information 
missing (77) 
No liver 
inflammation (2) 
High grades of liver 
inflammation (103) 
Low grades of liver 
inflammation (569) 
24 weeks therapy 
completed (876) 
Liver biopsy 
diagnostic (751) 
Figure 1 Flow Diagram of the Chronic Hepatitis C patients at each stage of the study. This flow diagram indicates number of patients
(mentioned in brackets) at each stage of this retrospective cohort study.
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comparable to a study by Zuberi BF in Karachi which
reported mean age of males as 35.9(SD8.0) years and that
in females as 39.1 (SD 9.1) years [26].
Table 1 Baseline characteristics of patients who did not complete the therapy and those who completed it
Study variable Did not complete treatment Completed treatment P-value
nL Response to variable nC Response to variable
Age: n (%) 120 876
< 40 year 79 (65.8) 534 (61.0) 0.31a
≥ 40 year 41 (34.2) 342 (39.0)
Gender: n (%) 120 876 0.20a
Male 65 (54.2) 417 (47.6)
Female 55 (45.8) 459 (52.4)
Marital Status: n (%) 120 876 0.46a
Single 18(15.0) 107(12.2)
Married 102(85.0) 769(87.8)
HCV genotype n (%) 10 91 0.85b
Genotype 1 0 (0) 1 (1.1)
Genotype 2 1 (10) 3 (3.3)
Genotype 3 9 (90.0) 86 (94.5)
Genotype 4 0 (0) 1 (1.1)
Viral load in IU/mL(median(IQR)) 16 594,217(16,481–29,445,155) 125 508,551(493–79,121,294) 0.30c
ALT in U/L(median(IQR)) 108 79.5(16–957) 796 72(11–781) 0.45c
AST in U/L (median(IQR)) 21 69(23–230) 151 46(14–508) 0.03c
Bilirubin in mg/dL(mean ± SD) 82 0.99 ± 0.44 553 0.89 ± 0.40 0.05d
Alkaline Phosphatase in U/L (mean ± SD) 82 218.8 ± 77.8 535 207.4 ± 98.7 0.31d
Albumin in g/dL (mean ± SD) 23 4.3 ± 0.4 170 4.2 ± 0.6 0.32d
Alpha Fetoprotein in ng/mL (median(IQR)) 6 2.18(0.5–10.4) 63 2.4(0.2–16.5) 0.85c
Hb in g/dL (mean ± SD) 116 15.4 ± 14.2 826 13.7 ± 5.07 0.01d
TLC in cell × 109/L(mean ± SD) 114 8.7 ± 8.8 805 7.5 ± 2.6 0.002d
a-Chi-square test, b-Fisher’s exact test, c-Mann Whitney-U test, d-Student’s t-test; nL: no. of patients who did not complete treatment, nC: no. of patients who
completed treatment.
Table 2 Demographic characteristics and pre-treatment
blood CP of patients with high and low grades of
inflammation
Study variable High grades of
inflammation
Low grades of
inflammation
P- Value
n1 Response to
variable
no Response to
variable
Demographic Characteristics
Age 0.031a
< 40 years 53 51.4% 357 62.7%
≥ 40 years 50 48.5% 212 37.2%
Gender 0.94a
Males 48 46.6% 263 46.2%
Females 55 53.4% 306 53.8%
Pre-treatment Blood CP
Hb in g/dL (mean ± SD) 94 15.0 ± 4 .1 540 13.6 ± 1.9 0.025b
TLC in cell ×109/L
(mean ± SD)
92 7.5 ± 2.4 527 7.5 ± 2.0 0.882b
a-Chi-square test,b-Student’s t-test; n1: number of patients in High
inflammation group, no: number of patients in low inflammation group.
Table 3 Pre-treatment biochemical tests of patients with
high and low grades of liver inflammation
Study variable High grades of
inflammation
Low grades of
inflammation
P- Value
n1 Response to
variable
no Response to
variable
Pre-treatment Biochemical tests
ALT in U/L
(mean ± SD)
87 119.2 ± 76.6 508 85.6 ± 66.6 <0.01a
AST in U/L
(median & IQR)
17 69 (22–229) 104 42 (14–508) 0.17b
Bilirubin in mg/dL
(mean ± SD)
62 0.9 ± 0.3 370 0.9 ± 0.4 0.67a
Alkaline phosphatase
in U/L (mean ± SD)
61 203 ± 131.6 356 207.3 ± 98.7 0.78a
Albumin in g/dL
(mean ± SD)
29 3.0 ± 0.4 110 4.1 ± 0.4 0.04a
a- Student’s t-test,b- Mann Whitney U test, n1: number of patients in High
inflammation group, no: number of patients in low inflammation group.
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Serum albumin level in patients with high grades liver
inflammation was significantly less than those in low
grades of inflammation group . This can be explained by
strong positive correlation of liver inflammation with
stage of fibrosis (correlation coefficient gamma= 0.724).
When inflammation grade increases, fibrosis increases
and serum albumin level decrease [27].
According to a study by Davis GL et al., TLC was a
potential predictor of response to recombinant Inter-
feron therapy at univariable analysis (p-value< 0.15),
along with dose of recombinant Interferon, weight, and
body surface area, ongoing use of ethanol and presence
of symptoms [28]; at multivariable analysis only dose of
recombinant Interferon was a predictor of response [28].
Findings of the current study is contrary to that of the
above as TLC of less than 7.2 × 109 cells/L had
independent positive association with positive ETR
adjusting for age, grade of liver inflammation and pre-
treatment ALT at the multivariable analysis. Reasons for
this variation need further investigation.
Increase in the grade of liver inflammation, tended to
correlate with increasing mean levels of pretreatment
ALT. This finding is similar to a study conducted in Iran
in which the median score of modified HAI was lower
in patients with normal ALT (defined as≤ 49 U/L) com-
pared to those with elevated ALT level (median score of
modified HAI 5 vs. 6, p-value: 0.001) [29]. This indicates
that serum ALT levels could be used to point towards
the increasing grade of liver inflammation. However, to
be used with caution as ROC curve analysis in this study
showed that ALT is moderately acceptable test for severe
liver inflammation.
One of the strengths of this study is its retrospective
design which made it resource efficient. Data source of
this study were medical records and laboratory reports
which is an efficient way of gaining information and
answering the research question. Much of the variables
studied were laboratory, radiology, and pathology based;
hence more objective compared to other data available
in records; as lab based tests are done consistently for all
and are readily available. The results obtained in this
study could be a result of chance; though unlikely. This
is supported by the precise 95% confidence intervals.
An important issue that may have affected the results
is loss to follow-up bias as 12%(n = 120) of the CHC
patients in eligible cohort did not complete the 24 week
therapy and hence were excluded; had they responded
positively (RR 1.14, 95% CI 1.14–1.20) or negatively (RR
1.18, 95% CI 1.14–1.20) to 24 weeks therapy, our results
may not have changed .We are confident that loss to
Table 4 Relationship between grades of inflammation
and End of Treatment Response (ETR) by Unadjusted RR
Variable n RR 95% CI RR
Grade of inflammation:
Low grades (Reference) 569 1 –
High grades 103 1.05 0.97–1.09
Age:
<40 years 410 1.11 1.08–1.15
≥40 years (Reference) 262 1 –
Gender:
Female (Reference) 361 1 –
Male 311 1.03 1.02-1.04
Pretreatment TLC cells × 109/L (1 unit rise) 619 0.98 0.98–0.99
Pretreatment ALT in U/L (5 unit rise) 595 1 0.99–1.001
Early viral response(EVR)
Negative (Reference) 92 1 –
Positive 250 1.6 1.4–1.8
RR: Risk Ratio.
Table 5 Relationship between grades of inflammation
and End of Treatment Response by adjusted RR (N=552)
Variable n RR 95% CI RR
Grade of inflammation
Low grades (Reference) 472 1 –
High grades 80 1.17 1.12–1.18
Age
< 40 years 334 1.16 1.11–1.23
≥ 40 years (Reference) 218 1 –
TLC
< 7.2 cells × 109/L 266 1.14 1.10–1.17
≥7.2 cells × 109/L (Reference) 286 1 –
ALT in U/L (5 unit rise) 552 1 0.99–1.01
RR: Risk Ratio.
Figure 2 Mean level of pre-treatment ALT in male and females
for various grade of liver inflammation. This figure depicts that as
liver inflammation increases, ALT level rises. ALT levels are higher for
males as compared to the females at all grades of liver
inflammation.
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follow-up bias was not substantial although they differed
on levels of Hb, TLC and bilirubin significantly.
Another source of measurement errors could be
related to assessment of liver biopsy by different pathol-
ogists. Study by Westin J et al. showed 95–96% agree-
ment between 3 pathologists grading liver biopsy on the
basis of modified HAI [30]. In the current study, 267 bi-
opsies were reported by a single pathologist; hence we
evaluated this subgroup of patients’ data for relationship
of positive ETR and grades of liver inflammation; which
obviously was not significant (RR 1.09, 95% CI 0.93–
1.14); due to the small insufficient sample size (post hoc
power reduced to 43.5% for subgroup analysis); however
the direction of relationship tended to be along with the
Figure 3 ROC curve for validity of pretreatment ALT for severe
vs. minimal inflammation. Part ‘a’ shows AUROC of pre-treatment
ALT for severe compared to minimal liver inflammation in males,
having a value of 0.871. Part ‘b’ shows AUROC of pre-treatment ALT
for severe compared to minimal liver inflammation in females, a
value of 0.744. Pre-treatment ALT is moderately accurate in
measuring severe as compared to minimal liver inflammation in
both genders, more in males as compared to the females.
Figure 4 ROC curve for validity of pretreatment ALT for mild
vs. minimal inflammation. Part ‘a’ shows AUROC of pre-treatment
ALT for mild compared to minimal liver inflammation in males,
having a value of 0.629. Part ‘b’ shows AUROC of pre-treatment ALT
for mild compared to minimal liver inflammation in females, a value
of 0.638. Pre-treatment ALT is less accurate in measuring mild as
compared to minimal inflammation in both genders.
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study results. Nevertheless interobservor agreement for
reporting inflammation grades of liver could not be
ruled out in this study.
Clinically, SVR is more relevant in following response
to Interferon α and Ribavirin therapy than ETR. The
patients with ETR positive are more than 20 times likely
to have SVR positive [31]. This study was aimed to see
the relationship of liver inflammation with ETR in naïve
CHC patients so data regarding SVR was not gathered.
Given the positive relationship between the two (higher
the liver inflammation, higher the ETR- in those having
bridging fibrosis and cirrhosis), future study will be con-
ducted to explore the relationship between liver inflam-
mation and SVR.
Of all the patients in whom HCV genotype data was
available (n = 101), 1.1% had HCV genotype 1 who re-
quire 48 weeks Interferon therapy instead of 24 weeks.
Thus the response in these patients may have been less
as compared to those having HCV genotype 2 or 3. But
as HCV genotype is not associated with liver inflamma-
tion [32], it may not have confounded the relationship
between the liver inflammation and ETR.
HCV genotype 3 prevalence as found in this study is
consistent with the reported proportion of HCV geno-
type 3 as 87. 8% in a study conducted by Mumtaz K
et al. in Karachi in 2008 [33]. Approximately 5% patients
in the current study had cirrhosis on liver biopsy. Idrees
M et al. in their multicentre study in Pakistan reported
the proportion of patients with cirrhosis on liver biopsy
as 4% [34]. Including the similarity in mean age of popu-
lation with other studies as mentioned above shows that
patient population of this study is reasonably representa-
tive of HCV patients in Pakistan; and therefore could be
generalized for the target population.
Conclusions
This study shows that treating physicians should start
treatment of CHC patients at an early age for favorable
response. Patients having higher grades of liver inflam-
mation (moderate or severe) will respond more to the
Interferon α and Ribavirin therapy. Though liver biopsy
is not done routinely, higher levels of serum ALT can
point towards severe inflammation. Other liver function
tests like low levels of serum albumin also reflect high
grades of liver inflammation.
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